Profound Medical Corp
TSX:PRN
Gross Margin
Profound Medical Corp
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CA |
|
Profound Medical Corp
TSX:PRN
|
208.9m CAD |
68%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
227.4B USD |
56%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
192.2B USD |
67%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
154.6B USD |
69%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
143.9B USD |
65%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.4B USD |
66%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52.2B EUR |
39%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
49.1B USD |
45%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.1B USD |
79%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
40.5B USD |
61%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
281.2B CNY |
61%
|
Profound Medical Corp
Glance View
Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Profound Medical Corp's most recent financial statements, the company has Gross Margin of 67.6%.
You don't have any saved screeners yet